bladder cancer

Bladder cancer is a disease in which certain cells in the bladder become abnormal and multiply without control or order. The bladder is a hollow, muscular organ in the lower abdomen that stores urine until it is ready to be excreted from the body. The most common type of bladder cancer begins in cells lining the inside of the bladder and is called transitional cell carcinoma (TCC).

Bladder cancer may cause blood in the urine, pain during urination, frequent urination, or the feeling that one needs to urinate without results. These signs and symptoms are not specific to bladder cancer, however. They also can be caused by noncancerous conditions such as infections.

Frequency

In the United States, bladder cancer is the fourth most common type of cancer in men and the ninth most common cancer in women. About 45,000 men and 17,000 women are diagnosed with bladder cancer each year.

Genetic Changes

As with most cancers, the exact causes of bladder cancer are not known; however, many risk factors are associated with this disease. Many of the major risk factors are environmental, such as smoking and exposure to certain industrial chemicals. Studies suggest that chronic bladder inflammation, a parasitic infection called schistosomiasis, and some medications used to treat cancer are other environmental risk factors associated with bladder cancer.

Genetic factors are also likely to play an important role in determining bladder cancer risk. Researchers have studied the effects of mutations in several genes, including *FGFR3*, *RB1*, *HRAS*, *TP53*, and *TSC1*, on the formation and growth of bladder tumors. Each of these genes plays a critical role in regulating cell division by preventing cells from dividing too rapidly or in an uncontrolled way. Alterations in these genes may help explain why some bladder cancers grow and spread more rapidly than others.

Deletions of part or all of chromosome 9 are common events in bladder tumors. Researchers believe that several genes that control cell growth and division are probably located on chromosome 9. They are working to determine whether a loss of these genes plays a role in the development and progression of bladder cancer.

Most of the genetic changes associated with bladder cancer develop in bladder tissue during a person's lifetime, rather than being inherited from a parent. Some people, however, appear to inherit a reduced ability to break down certain chemicals, which

makes them more sensitive to the cancer-causing effects of tobacco smoke and industrial chemicals.

Inheritance Pattern

Bladder cancer is typically not inherited. Most often, tumors result from genetic mutations that occur in bladder cells during a person's lifetime. These noninherited genetic changes are called somatic mutations.

Other Names for This Condition

- Cancer of the bladder
- Malignant tumor of urinary bladder
- Urinary bladder cancer

Diagnosis & Management

Genetic Testing

 Genetic Testing Registry: Malignant tumor of urinary bladder https://www.ncbi.nlm.nih.gov/gtr/conditions/C0005684/

Other Diagnosis and Management Resources

 MedlinePlus Encyclopedia: Bladder Cancer https://medlineplus.gov/ency/article/000486.htm

General Information from MedlinePlus

- Diagnostic Tests https://medlineplus.gov/diagnostictests.html
- Drug Therapy https://medlineplus.gov/drugtherapy.html
- Genetic Counseling https://medlineplus.gov/geneticcounseling.html
- Palliative Care https://medlineplus.gov/palliativecare.html
- Surgery and Rehabilitation https://medlineplus.gov/surgeryandrehabilitation.html

Additional Information & Resources

MedlinePlus

 Encyclopedia: Bladder Cancer https://medlineplus.gov/ency/article/000486.htm

 Health Topic: Bladder Cancer https://medlineplus.gov/bladdercancer.html

Genetic and Rare Diseases Information Center

 Bladder cancer https://rarediseases.info.nih.gov/diseases/12210/bladder-cancer

Additional NIH Resources

- National Cancer Institute: Bladder Cancer Home Page https://www.cancer.gov/types/bladder
- National Cancer Institute: What You Need To Know About Bladder Cancer https://www.cancer.gov/publications/patient-education/wyntk-bladder-cancer

Educational Resources

- Disease InfoSearch: Bladder cancer http://www.diseaseinfosearch.org/Bladder+cancer/7822
- M. D. Anderson Cancer Center https://www.mdanderson.org/cancer-types/bladder-cancer.html
- MalaCards: bladder cancer, somatic http://www.malacards.org/card/bladder_cancer_somatic
- Merck Manual Consumer Version http://www.merckmanuals.com/home/kidney-and-urinary-tract-disorders/cancersof-the-kidney-and-genitourinary-tract/bladder-cancer
- Orphanet: Bladder cancer http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=157980
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins http://www.hopkinsmedicine.org/kimmel_cancer_center/

Patient Support and Advocacy Resources

- American Cancer Society https://www.cancer.org/cancer/bladder-cancer.html
- National Coalition for Cancer Survivorship http://www.canceradvocacy.org

ClinicalTrials.gov

ClinicalTrials.gov
 https://clinicaltrials.gov/ct2/results?cond=%22bladder+cancer%22

Scientific Articles on PubMed

PubMed

https://www.ncbi.nlm.nih.gov/pubmed?term=%28Bladder+Neoplasms%5BMAJR %5D%29+AND+%28bladder+cancer%5BTI%5D%29+AND+review%5Bpt%5D +AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+360+days %22%5Bdp%5D

OMIM

 BLADDER CANCER http://omim.org/entry/109800

Sources for This Summary

- American Cancer Society: What Are the Key Statistics for Bladder Cancer? https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html
- Bryan RT, Hussain SA, James ND, Jankowski JA, Wallace DM. Molecular pathways in bladder cancer: part 1. BJU Int. 2005 Mar;95(4):485-90. Review.
 Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15705065
- Bryan RT, Hussain SA, James ND, Jankowski JA, Wallace DM. Molecular pathways in bladder cancer: part 2. BJU Int. 2005 Mar;95(4):491-6. Review.
 Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15705066
- Buscarini M, Quek ML, Gill P, Xia G, Quinn DI, Stein JP. Molecular prognostic factors in bladder cancer. BJU Int. 2005 Apr;95(6):739-42. Review.
 Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15794774
- Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B. Focus on bladder cancer. Cancer Cell. 2004 Aug;6(2):111-6. Review.
 Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15324694
- Lindgren D, Liedberg F, Andersson A, Chebil G, Gudjonsson S, Borg A, Månsson W, Fioretos T, Höglund M. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene. 2006 Apr 27;25(18):2685-96.
 Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16532037
- Mhawech-Fauceglia P, Cheney RT, Schwaller J. Genetic alterations in urothelial bladder carcinoma: an updated review. Cancer. 2006 Mar 15;106(6):1205-16. Review.
 Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16470587
- Oxford G, Theodorescu D. The role of Ras superfamily proteins in bladder cancer progression. J Urol. 2003 Nov;170(5):1987-93. Review.
 Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14532839

- Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol. 2003 Apr; 169(4):1219-28. Review.
 - Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12629332
- Syrigos KN, Karapanagiotou E, Harrington KJ. The clinical significance of molecular markers to bladder cancer. Hybrid Hybridomics. 2004 Dec;23(6):335-42. Review.
 Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15684659
- Wolff EM, Liang G, Jones PA. Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol. 2005 Oct;2(10):502-10. Review.
 Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16474624
- van Rhijn BW, van Tilborg AA, Lurkin I, Bonaventure J, de Vries A, Thiery JP, van der Kwast TH, Zwarthoff EC, Radvanyi F. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet. 2002 Dec;10(12): 819-24.

Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12461689

Reprinted from Genetics Home Reference:

https://ghr.nlm.nih.gov/condition/bladder-cancer

Reviewed: January 2007 Published: March 21, 2017

Lister Hill National Center for Biomedical Communications U.S. National Library of Medicine National Institutes of Health Department of Health & Human Services